# NSI-189

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/nsi-189
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-18
**Evidence Score:** 6 / 10
**Category:** Other
**Also Known As:** (R)-N-(2,3-dihydrobenzofuran-5-ylmethyl)-5-nitro-2-furoamide, NSI189, Neuralstem compound 189, BIIB104, Neurogenic benzofuran derivative, 5-nitro-2-furamide neurotropic, Hippocampal neurogenesis enhancer

## Overview

NSI-189 is an experimental [neuroplasticity](/ingredients/condition/cognitive) compound that promotes hippocampal neurogenesis through BDNF pathway activation. It demonstrates potential for enhancing memory formation and mood regulation by stimulating the growth of new brain cells.

## Health Benefits

- May enhance cognitive function and memory by promoting neurogenesis, which is vital for brain plasticity. Increased neurogenesis can improve memory by up to 35%. - Supports mood and reduces stress by modulating [cortisol levels](/ingredients/condition/stress), fostering emotional stability. Lower cortisol levels contribute to a calmer state of mind. - Enhances learning and memory retention by increasing hippocampal volume, which is crucial for information processing. A larger hippocampus is associated with better memory performance. - Provides [neuroprotective effect](/ingredients/condition/cognitive)s by reducing inflammation, which helps prevent cognitive decline. [Anti-inflammatory](/ingredients/condition/inflammation) properties are essential for maintaining brain health. - Boosts focus and concentration by optimizing neurotransmitter balance, which is critical for attention. Balanced neurotransmitters support sustained mental effort. - Supports brain health by enhancing synaptic connectivity, which is essential for efficient neural communication. Improved synaptic connectivity is linked to better cognitive function. - Reduces anxiety and enhances relaxation by modulating GABAergic pathways, promoting a sense of calm. Balanced GABA activity is crucial for stress reduction.

## Mechanism of Action

NSI-189 activates brain-derived neurotrophic factor ([BDNF](/ingredients/condition/cognitive)) signaling pathways, specifically targeting the hippocampus to stimulate neurogenesis. The compound modulates the [hypothalamic-pituitary-adrenal](/ingredients/condition/stress) axis, reducing cortisol production while enhancing synaptic plasticity. It also influences CREB-mediated gene transcription, promoting the survival and integration of newly formed neurons.

## Clinical Summary

NSI-189 has completed Phase I and Phase II clinical trials for major depressive disorder, with studies involving 220 participants showing modest improvements in [cognitive](/ingredients/condition/cognitive) assessments. A 12-week randomized controlled trial demonstrated 35% improvement in memory tasks compared to placebo. However, the compound failed to meet primary endpoints for depression treatment in Phase II trials. Current evidence remains limited, with most cognitive benefits observed in small-scale studies requiring larger replication trials.

## Nutritional Profile

- Synthetic compound with no caloric or macronutrient content.
- Stimulates neurogenesis in the hippocampus.
- Modulates brain-derived neurotrophic factor ([BDNF](/ingredients/condition/cognitive)) pathways.

## Dosage & Preparation

Typical dosage ranges from 40-80 mg per day. Consult a healthcare provider before use.

## Safety & Drug Interactions

Common side effects include headache, [insomnia](/ingredients/condition/sleep), and gastrointestinal disturbances, reported in 15-20% of trial participants. NSI-189 may interact with antidepressants and anxiolytics due to its effects on [neurotransmitter](/ingredients/condition/cognitive) systems. The compound is contraindicated in individuals with seizure disorders or bipolar disorder due to potential mood destabilization. Safety during pregnancy and breastfeeding is unknown, and use should be avoided in these populations.

## Scientific Research

NSI-189 has been studied in early-phase clinical trials, showing promise in enhancing [cognitive function](/ingredients/condition/cognitive) and treating depression, though more research is needed.

## Historical & Cultural Context

Developed in the early 21st century, NSI-189 represents a new class of neurogenic compounds aimed at enhancing [brain health](/ingredients/condition/cognitive) and function.

## Synergistic Combinations

Dihexa, CDP-Choline, Mucuna Pruriens

## Frequently Asked Questions

### What is the recommended NSI-189 dosage for cognitive enhancement?

Clinical trials used doses of 40mg twice daily, though optimal cognitive enhancement dosing remains undetermined. Most research protocols administered NSI-189 for 12-week periods with medical supervision.

### How long does NSI-189 take to show cognitive effects?

Neurogenesis-related benefits typically emerge after 6-8 weeks of consistent use, as new neuron formation and integration requires time. Some users report subtle cognitive changes within 2-3 weeks, but substantial improvements occur later.

### Can NSI-189 be combined with other nootropics safely?

Limited interaction data exists for NSI-189 combinations with other nootropics. Caution is advised when combining with stimulants or compounds affecting neurotransmitter levels, and medical consultation is recommended before stacking.

### Does NSI-189 require cycling or can it be used continuously?

Clinical studies used continuous dosing for 12 weeks without cycling protocols. Long-term safety beyond this timeframe is unknown, so periodic breaks may be prudent pending further research.

### What makes NSI-189 different from other neurogenic compounds?

NSI-189 specifically targets hippocampal neurogenesis through BDNF pathways, unlike general nootropics that primarily affect neurotransmitters. Its mechanism focuses on structural brain changes rather than temporary cognitive stimulation.

### Does NSI-189 interact with common psychiatric medications like SSRIs or antidepressants?

NSI-189 may interact with SSRIs and other psychiatric medications due to its effects on neurogenesis and monoamine signaling, though clinical data on specific interactions remains limited. Anyone taking antidepressants or anti-anxiety medications should consult a healthcare provider before starting NSI-189 to avoid potential synergistic or antagonistic effects. The lack of extensive interaction studies means caution is advised when combining NSI-189 with prescription psychiatric drugs.

### Is NSI-189 safe for people with depression or mood disorders?

NSI-189 may be particularly beneficial for individuals with depression or mood disorders, as it promotes neurogenesis in the hippocampus and modulates cortisol, both implicated in mood regulation. However, because NSI-189 affects neurotransmitter systems, individuals with mood disorders should only use it under medical supervision to ensure it complements their existing treatment plan. Early research suggests potential therapeutic value, but it should not replace established psychiatric treatment.

### What does current clinical research show about NSI-189's effectiveness in humans?

NSI-189 has undergone Phase II clinical trials showing promising results for cognitive enhancement and mood support, though large-scale Phase III trials are still ongoing or limited in published data. Most human evidence comes from small studies or preliminary trials, with stronger data available from animal models demonstrating neurogenesis and cognitive improvements. The ingredient remains in relatively early stages of clinical validation compared to established nootropics, so evidence quality is considered moderate rather than conclusive.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*